Skip to main content
Fig. 8 | Cancer Cell International

Fig. 8

From: Targeting HER2-positive breast cancer cells by a combination of dasatinib and BMS-202: Insight into the molecular pathways

Fig. 8

Molecular pathways analysis of DA (5 µM) and BMS-202 (5 µM) in (a) SKBR3 and (b) ZR75 cell lines after 48 h of treatment. DA and BMS-202 inhibitors together reduce the phosphorylation of ErbB2 and AKT, as well as the expression of JNK1/2/3 in both cell lines in comparison with those treated with DA and BMS-202 individually and control cells. GAPDH was used as a control for the amount of protein in this assay. Data are expressed as protein expression ± SEM

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us